Evidence map›Paper›PMID 35561450›Full record

ArticleEBioMedicine2022

Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis.

Michael Hecker, Brit Fitzner, Elena Putscher, Margit Schwartz, Alexander Winkelmann, Stefanie Meister, Ales Dudesek, Dirk Koczan, Peter Lorenz, Nina Boxberger and 1 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. C1q and central nervous system disorders.Frontiers in immunology · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Michael HeckerDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany. Electronic address: michael.hecker@rocketmail.com.
Brit FitznerDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Elena PutscherDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Margit SchwartzDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Alexander WinkelmannDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Stefanie MeisterDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Ales DudesekDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Dirk KoczanInstitute of Immunology, Rostock University Medical Center, Schillingallee 70, Rostock 18057, Germany.
Peter LorenzInstitute of Immunology, Rostock University Medical Center, Schillingallee 70, Rostock 18057, Germany.
Nina BoxbergerDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
Uwe Klaus ZettlDepartment of Neurology, Division of Neuroimmunology, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany.
University of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a well-established genetic contribution to susceptibility. Over 200 genetic regions have been linked to the inherited risk of developing MS, but the disease-causing variants and their functional effects at the molecular level are still largely unresolved. We hypothesised that MS-associated single-nucleotide polymorphisms (SNPs) affect the recognition and enzymatic cleavage of primary microRNAs (pri-miRNAs).

methodsOur study focused on 11 pri-miRNAs (9 primate-specific) that are encoded in genetic risk loci for MS. The levels of mature miRNAs and potential isoforms (isomiRs) produced from those pri-miRNAs were measured in B cells obtained from the peripheral blood of 63 MS patients and 28 healthy controls. We tested for associations between SNP genotypes and miRNA expression in cis using quantitative trait locus (cis-miR-eQTL) analyses. Genetic effects on miRNA stem-loop processing efficiency were verified using luciferase reporter assays. Potential direct miRNA target genes were identified by transcriptome profiling and computational binding site assessment.

findingsMature miRNAs and isomiRs from hsa-mir-26a-2, hsa-mir-199a-1, hsa-mir-4304, hsa-mir-4423, hsa-mir-4464 and hsa-mir-4492 could be detected in all B-cell samples. When MS patient subgroups were compared with healthy controls, a significant differential expression was observed for miRNAs from the 5' and 3' strands of hsa-mir-26a-2 and hsa-mir-199a-1. The cis-miR-eQTL analyses and reporter assays pointed to a slightly more efficient Drosha-mediated processing of hsa-mir-199a-1 when the MS risk allele T of SNP rs1005039 is present. On the other hand, the MS risk allele A of SNP rs817478, which substitutes the first C in a CNNC sequence motif, was found to cause a markedly lower efficiency in the processing of hsa-mir-4423. Overexpression of hsa-mir-199a-1 inhibited the expression of 60 protein-coding genes, including IRAK2, MIF, TNFRSF12A and TRAF1. The only target gene identified for hsa-mir-4423 was TMEM47.

interpretationWe found that MS-associated SNPs in sequence determinants of pri-miRNA processing can affect the expression of mature miRNAs. Our findings complement the existing literature on the dysregulation of miRNAs in MS. Further studies on the maturation and function of miRNAs in different cell types and tissues may help to gain a more detailed functional understanding of the genetic basis of MS.

fundingThis study was funded by the Rostock University Medical Center (FORUN program, grant: 889002), Sanofi Genzyme (grant: GZ-2016-11560) and Merck Serono GmbH (Darmstadt, Germany, an affiliate of Merck KGaA, CrossRef Funder ID: 10.13039/100009945, grant: 4501860307). NB was supported by the Stiftung der Deutschen Wirtschaft (sdw) and the FAZIT foundation. EP was supported by the Landesgraduiertenförderung Mecklenburg-Vorpommern.

Indexed as

MicroRNAsMultiple SclerosisBinding SitesGene Expression ProfilingHumansPolymorphism, Single NucleotideMicroRNAsB cellsExpression quantitative trait lociGenetic riskImmune reconstitution therapyMicroRNAsMicroRNA target genesMultiple sclerosisPrimary microRNA processingSingle-nucleotide polymorphisms

Identifiers

PMID35561450
PMCPMC9111935
OpenAlexW4280553572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.